Day: August 10, 2023

WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. “In the second quarter, and throughout the first half of 2023, we steadily advanced our REACT development programs, including our initial Phase 3 study, proact 1, that is assessing the potential for REACT to delay or halt the progression of moderate to severe diabetic CKD,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Looking ahead, we expect to reach several important inflection points in the coming months, including updated interim...

Gross profit margin increased to 50.2%, an improvement of 140 basis points sequentially Reaffirms Net Revenue guidance for the full year of 2023 of at least $305 million and Adjusted EBITDA from continuing operations1 of at least $58 million TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today reported its financial results for the second quarter ended June 30, 2023. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise. The following financial measures are reported as results from continuing operations due to the shutdown of the licensed producer business in Canada, which is reported as discontinued operations for all of 2022....

MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2023. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2023 and Recent Highlights PartnershipsDivestiture of assets within eflornithine (DFMO) pediatric neuroblastoma program to US WorldMeds® for an upfront payment of $400,000 and contingent payments totaling up to an additional $9.1 million. Regained the North American rights to develop and commercialize Flynpovi tm (the combination of CPP-1X (eflornithine) and sulindac) in patients with familial adenomatous polyposis (FAP).ClinicalOpened...

First Patients Dosed in Phase 2a Clinical Trial of SLS009 (formerly GFH009) in Acute Myeloid Leukemia with Topline Data Expected in 4Q 2023 Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia on Track for Interim Analysis by Late 2023/Early 2024 REGAL Independent Data Monitoring Committee to Meet in 3Q 2023 NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2023. “We are pleased with the solid progress across our clinical programs in the first half of the year. We expect to complete enrollment in our Phase...

Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) — Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q3 FY 2023”) and nine months (“YTD FY 2023”) ended June 30, 2023. Financial Highlights Q3 FY 2023 HighlightsRevenue was $157.5 million in Q3 FY 2023 as compared to $172.7 million during the three months ended June 30, 2022 (“Q3 FY 2022”), driven by a $2.4 million, or 5.0%, decrease in Discovery and Safety Assessment (“DSA”) revenue and a $12.7 million, or 10.3%, decrease in Research Models and Services (“RMS”) revenue. Consolidated...

SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Shift Technologies, Inc. (Nasdaq: SFT) (“Shift” or the “Company”), a consumer-centric omnichannel retailer for buying and selling used cars, today reported second quarter financial results for the period ended June 30, 2023. Management’s commentary on second quarter financial results can be found by accessing the Company’s prepared remarks on investors.shift.com, or by listening to today’s conference call. A live audio webcast will also be available on Shift’s Investor Relations website. The following represents a summary of certain operating results (unaudited). Reconciliations and descriptions of non-GAAP financial measures to corresponding GAAP financial measures are included in the tables at the end of this press release. Second Quarter 2023 Operating ResultsTotal revenue for...

Genasys Protect Re-Brand and Launch Underway SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the leader in Protective Communications solutions, today announced financial results for the Company’s fiscal third quarter ended June 30, 2023. Richard S. Danforth, Chief Executive Officer of Genasys, Inc., commented, “As expected, revenues for the June quarter improved versus the second quarter and were in line with the year-ago quarter. Adjusted EBITDA improved sequentially but was lower year over year, reflecting the ongoing investment in Genasys Protect. With recurring revenue up 47% year over year, and year-to-date software bookings up 180%, I am more confident than ever in our strategic investment in diversifying our business.”  Mr. Danforth continued, “The steady growth and expansion of our recurring software...

Conference Call on Thursday, August 10, 2023, at 9 p.m. ET with Accompanying Investor Presentation BEIJING, Aug. 10, 2023 (GLOBE NEWSWIRE) — ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students’ creativity, today announced preliminary unaudited financial results for the quarter and six months ended June 30, 2023 (“Second Quarter 2023” and “First Half 2023”, respectively). Second Quarter 2023 and First Half 2023 HighlightsDuring Second Quarter 2023, student enrollment was 928, compared to 1,018 in the prior-year period. Excluding the 155 enrollments from the foreign language training business ACG disposed of in Third Quarter 2022, student enrollment increased by 7.5% compared to the prior-year...

Analytics Recurring New Bookings* increased sequentially and year-over-year; successfully managed through Property Tax jurisdictional reset and delivered double-digit growth at Analytics TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Altus Group Limited (ʺAltus” or “the Company”) (TSX: AIF), a leading provider of asset and fund intelligence for commercial real estate (“CRE”), announced today its financial and operating results for the second quarter ended June 30th, 2023 and the approval by its Board of Directors of the payment of a cash dividend of $0.15 per common share for the third quarter ending September 30, 2023. Unless otherwise indicated, all amounts are in Canadian dollars and percentages are on an as reported basis in comparison to Q2 2022. Q2 2023 SummaryConsolidated revenues were $205.2 million, down 0.6% (4.1% on a...

SHAKOPEE, Minn., Aug. 10, 2023 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (NASDAQ: CPHC), today reported financial results for the three and six months ended June 30, 2023. ($ in thousands, except per share data and percentages)  Three Months Ended June 30,   Six Months Ended June 30,    2023     2022   Change     2023     2022   ChangeNet revenues $ 16,342   $ 17,774   -8.1 %   $ 29,641   $ 31,412   -5.6 %                       Net income $ 5,293   $ 1,755   201.6 %   $ 8,063   $ 3,529   128.5 %                       Adjusted EBITDA (1) $ 2,020   $ 3,564   -43.3 %   $ 4,502   $ 7,111   -36.7 %                       Basic EPS $ 1.08   $ 0.36   200.0 %   $ 1.64   $ 0.73   124.7 %Diluted EPS $ 1.07   $ 0.36   197.2 %   $ 1.64   $ 0.73   124.7 %                                   (1)   Adjusted...